Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 3, 2006, Pages 928-934

  Shelton, Mark J ^a   Wire, Mary Beth ^a   Lou, Yu ^a   Adamkiewicz, Brigette ^a   Min, Sherene S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPRENAVIR PHOSPHATE; ASPARTATE AMINOTRANSFERASE; RITONAVIR;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIZZINESS; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LOOSE FECES; MACULOPAPULAR RASH; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; NUTRITIONAL DISORDER; ORAL PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; STEADY STATE; THROAT IRRITATION; VOMITING;

ADOLESCENT; ADULT; CARBAMATES; CLINICAL TRIALS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; RITONAVIR; SULFONAMIDES;

EID: 33644645264     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.3.928-934.2006     Document Type: Article

References (14)

1. Autar, R. S., J. Ananworanich, W. Apateerapong, J. Sankote, A. Hill, B. Hirchel, D. Cooper, J. Lange, P. Phanuphak, K. Ruxrungtham, and D. Burger. 2004. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1 infected patients: 1,600/100 mg once-daily compared with 2,000/100 mg once-daily and 1,000/100 mg twice-daily. J. Antimicrob. Chemother. 54:785-790.
2. Boffito, M., D. Maitland, Y. Samarasinghe, and A. Pozniak. 2005. The pharmacokinetics of HIV protease inhibitor combinations. Curr. Opin. Infect. Dis. 18:1-7.
3. Cooper, C. L., R. P. van Heeswijk, K. Gallicano, and D. W. Cameron. 2003. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin. Infect. Dis. 36:1585-1592.
4. Gathe, J. C., P. Ive, R. Wood, D. Schurmann, N. C. Bellos, E. DeJesus, A. Gladysz, C. Garris, and J. Yeo. 2004. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1 infected patients. AIDS 18:1529-1537.
5. Hsu, A., G. R Granneman, G. Witt, C. Locke, J. Dennisen, A. Molla, et al. 1997. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:898-905.
6. Kilby, J. M., G. Sfakianos, N. Gizzi, P. Siemon-Hryczyk, E. Ehrensing, C. Oo., N. Buss, and M. S. Saag. 2000. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob. Agents Chemother. 44:2672-2678.
7. Moyle, G. J., and D. Back. 2001. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2:105-113.
8. Murphy, R. L., S. Brun, C. Hicks, J. J. Eron, R. Gulick, M. King, A. C. White Jr., C. Benson, M. Thompson, H. A. Kessler, S. Hammer, R. Bertz, A. Hsu, A. Japour, and E. Sun. 2001. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral naïve adults with HIV-1 infection: 48-week results. AIDS 15:F1-F9.
9. Purnell, J. Q., A. Zambon, R. H. Knopp, D. J. Pizzuti, R. Achari, J. M. Leonard, C. Locke, and J. D. Brunzell. 2000. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14:51-57.
10. Rodriguez-French, A., J. Boghossian, G. E. Gray, J. P. Nadler, A. R. Quinones, G. E. Sepulveda, J. M. Millard, and P. G. Wannamaker. 2004. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve human immunodeficiency virus type 1 (HIV-1)-infected patients. J. Acquir. Immune Defic. Syndr. 35:22-32.
11. Saah, A. J., A. G. Winchell, M. L. Nessly, M. A. Seniuk, R. R. Rhodes, and P. J. Deutsch. 2001. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob. Agents Chemother. 45:2710-2715.
12. Sadler, B. M., P. J. Piliero, S. L. Preston, P. P. Lloyd, Y. Lou, and D. Stein. 2001. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 15:1009-1018.
13. Shafran, S. D., L. D. Mashinter, and S. E. Roberts. 2005. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 6:421-425.
14. Wire, M. B., C. Ballow, S. L. Preston, C. W. Hendrix, P. J. Piliero, Y. Lou, and D. S. Stein. 2004. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 18:897-907.